Home / Recalls / Novo Nordisk Inc. / D-0244-2026

D-0244-2026 Class II Ongoing

Recalled by Novo Nordisk Inc. — Plainsboro, NJ

Recall Details

Product Type: Drugs
Report Date: January 7, 2026
Initiation Date: December 19, 2025
Termination Date: N/A
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: N/A

Product Description

Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14

Reason for Recall

Presence of Particulate Matter: Hair was found in a prefilled syringe

Distribution Pattern

Nationwide within the United States.

Code Information

Lot #: RZFHD52, RZFHW93; Exp Date 10/31/2026

Other recalls by Novo Nordisk Inc.

D-0245-2026 Class II — Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manuf (December 19, 2025)
D-0619-2021 Class I — TRESIBA FlexTouch (insulin degludec injection) 100 units/mL (U-100), 3 mL Prefil (March 22, 2021)
D-0621-2021 Class I — TRESIBA FlexTouch (insulin degludec injection) 200 units/mL (U-200), 3 mL Prefil (March 22, 2021)
D-0611-2021 Class I — Fiasp FlexTouch (insulin aspart injection) 100 units/mL (U-100), 3 mL Prefilled (March 22, 2021)
D-0623-2021 Class I — Xultophy 100/3.6 (insulin degludec and liraglutide injection), 100 units/mL and (March 22, 2021)
D-0616-2021 Class I — NovoLog (Insulin aspart) Injection, 100 units/mL (U-100), One 10 mL multi-dose v (March 22, 2021)
D-0622-2021 Class II — ViCTOZA (liraglutide) injection, 18 mg/3 mL (6 mg/mL), contains: 1 Victoza Pen, (March 22, 2021)
D-0620-2021 Class I — TRESIBA (insulin degludec injection) 100 units/mL (U-100), One 10 mL multi-dose (March 22, 2021)
D-0614-2021 Class I — Levemir FlexTouch (insulin detemir) injection, 100 units/mL (U-100), 3 mL Prefil (March 22, 2021)
D-0613-2021 Class I — Fiasp (insulin aspart injection), 100 units/mL (U-100), One 10 mL multi-dose via (March 22, 2021)